Start up. Grow up. Succeed.

News 2011

Pieris AG Outlines Strategic Impact of Six Million Euro EUROCALIN Grant Award on Anticalin® Pipeline Development

In concert with the award of the EU FP7 Grant to the Pieris-led EUROCALIN Consortium that will enable

Pieris AG EUROCALIN Consortium Initiates EU Grant Funded Collaboration to Develop Novel Anticalin Therapeutic to Treat Anemia

Consortium Will Receive Six Million Euro from Seventh Framework Programme.The EUROCALIN Consortium, comprising 10 companies and universities from across Europe, has initiated a collaboration focused on attaining

Nexigen GmbH appoints Dr. Jörg Vollmer as CEO

Nexigen GmbH, a biopharmaceutical company developing therapeutic peptides to fight cancer, announced the appointment of Dr. Jörg Vollmer as CEO

IDENT Technology AG and AU Optronics Corporation partner to develop the world’s first 3D Gesture Multi-touch Display

IDENT Technology AG and AU Optronics Corporation today announced a strategic partnership to jointly develop a new generation of Multi-touch

Robert Bosch Venture Capital Investment in IDENT Technology AG to Launch 3D Gesture Control Chip

Together with existing investors MIG Funds and Danube Equity, Robert Bosch Venture Capital GmbH (RBVC) today announced the completion of a 7.1 million Euro investment round in IDENT Technology AG. The investment supports strong growth plans and the introduction of a 3D gesture recognition chip.

ARTIFICIAL Technology GmbH Cliffhanger Productions Relies on EKI One 2.6

Middleware from Artificial Technology used in new online strategy game ‘Jagged Alliance Online’

IDENT Technology AG receives further investment to move to fabless business model for its consumer market 3D gesture control chip

IDENT Technology AG, developer of innovative proximity sensing and gesture recognition solutions, has received a new round of investment to develop its GestIC three-dimensional (3D) gesture control chip solution using a fabless semiconductor business model.

Pieris AG and Daiichi Sankyo Sign Therapeutic Collaboration to Develop Anticalin® Therapeutics

Pieris AG announced today the signature of a collaboration and license agreement with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568),

Hepa Wash GmbH certified as medical device company according to ISO 13485

As a medical device company the Hepa Wash GmbH must meet the highest standards regarding the safety and reliability of its products and services.

VAXIMM AG closes a CHF 7.8 million financing round

Swiss biotech firm and Merck KGaA spin-off VAXIMM AG announced today the closing of a private financing round totaling CHF 7.8 million from new and existing investors. BB Biotech Ventures and Merck KGaA were joined by new investors Sunstone Capital, Merck Serono Ventures and BioMedPartners. The company plans to use the proceeds of the financing to progress its lead program VXM01 into and through clinical phase I testing.

Takeda San Francisco and Pieris AG Sign Anticalin® Therapeutic Collaboration

Takeda San Francisco (TSF) and Pieris AG have signed a drug discovery partnership agreement under which Pieris will apply its Anticalin® scaffold technology to deliver protein therapeutic candidates to Takeda, both companies announced today.

MAB Discovery GmbH: PPD Establishes Joint Venture for Drug Discovery of Large Molecules

BioDuro Biologics to build on BioDuro's strong global drug discovery services PPD, Inc. (Nasdaq: PPDI) today announced it has established a joint venture with Taijitu Biologics Limited (TBL) in the area of the discovery of novel biotherapeutics.

Hepa Wash GmbH awarded ZIM Grant

Federal Ministry of Economic Affairs supports the development of production line for Hepa Wash fluids with € 125,000